Psoriasis

<section class="Section" data-sectioncode="34089-3"><a name="section-8"></a><h1>11 DESCRIPTION</h1>Risankizumab-rzaa, an interleukin-23 (IL-23) antagonist, is a humanized immunoglobulin G1 (IgG1) monoclonal antibody. Risankizumab-rzaa is produced by recombinant DNA technology in Chinese hamster ovary cells and has an approximate molecular weight of 149 kDa. SKYRIZI (risankizumab-rzaa) injection 75 mg/0.83 mL prefilled syringe for subcutaneous useEach SKYRIZI prefilled syringe contains a sterile, preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution. Each syringe delivers 75 mg of risankizumab-rzaa, and the inactive ingredients polysorbate 20 (0.17 mg), sodium succinate (0.53 mg), sorbitol (34 mg), succinic acid (0.049 mg), and Water for Injection, USP. The pH is 6.2.SKYRIZI (risankizumab-rzaa) injection 90 mg/mL prefilled syringe for subcutaneous useEach SKYRIZI prefilled syringe contains a sterile, preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution. Each syringe delivers 90 mg of risankizumab-rzaa, and inactive ingredients polysorbate 20 (0.2 mg), sodium succinate (0.63 mg), sorbitol (41 mg), succinic acid (0.059 mg), and Water for Injection, USP. The pH is 6.2.SKYRIZI (risankizumab-rzaa) injection 150 mg/mL prefilled syringe or prefilled pen for subcutaneous use Each SKYRIZI prefilled pen or prefilled syringe contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each syringe and pen delivers 150 mg of risankizumab-rzaa and the inactive ingredients glacial acetic acid (0.054 mg), polysorbate 20 (0.2 mg), sodium acetate (0.75 mg), trehalose (63.33 mg), and Water for Injection, USP. The pH is 5.7.SKYRIZI (risankizumab-rzaa) injection 180 mg/1.2mL (150 mg/mL) prefilled cartridge for use with supplied on-body-injector for subcutaneous useEach SKYRIZI prefilled cartridge contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each cartridge delivers 180 mg of risankizumab-rzaa, and the inactive ingredients glacial acetic acid (0.065 mg), polysorbate 20 (0.24 mg), sodium acetate (0.9 mg), trehalose (76 mg), and Water for Injection, USP. The pH is 5.7.SKYRIZI (risankizumab-rzaa) injection 360 mg/2.4 mL (150 mg/mL) prefilled cartridge for use with the supplied on-body injector for subcutaneous use Each SKYRIZI prefilled cartridge contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each cartridge delivers 360 mg of risankizumab-rzaa, and the inactive ingredients glacial acetic acid (0.13 mg), polysorbate 20 (0.48 mg), sodium acetate (1.8 mg), trehalose (152 mg), and Water for Injection, USP. The pH is 5.7.SKYRIZI 600 mg/10 mL (60 mg/mL) in a vial for intravenous infusionSKYRIZI (risankizumab-rzaa) injection 600 mg/10 mL (60 mg/mL) is a sterile, preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution in a 10 mL single-dose vial.Each 10 mL single-dose vial contains 600 mg of risankizumab-rzaa, and the inactive ingredients glacial acetic acid (0.54 mg), polysorbate 20 (2 mg), sodium acetate (7.5 mg), trehalose (633.3 mg), and Water for Injection, USP. The pH is 5.7.</section>

Skyrizi

0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe

0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe [Skyrizi]

1 ML risankizumab-rzaa 150 MG/ML Auto-Injector

1 ML risankizumab-rzaa 150 MG/ML Auto-Injector [Skyrizi]

1 ML risankizumab-rzaa 150 MG/ML Prefilled Syringe

1 ML risankizumab-rzaa 150 MG/ML Prefilled Syringe [Skyrizi]

1.2 ML risankizumab-rzaa 150 MG/ML Cartridge

1.2 ML risankizumab-rzaa 150 MG/ML Cartridge [Skyrizi]

10 ML risankizumab-rzaa 60 MG/ML Injection

10 ML risankizumab-rzaa 60 MG/ML Injection [Skyrizi]

2.4 ML risankizumab-rzaa 150 MG/ML Cartridge

2.4 ML risankizumab-rzaa 150 MG/ML Cartridge [Skyrizi]

risankizumab

Summit Cancer Centers

Skyrizi | Summit Cancer Centers

Does Summit Cancer Centers work closely with Skyrizi and AbbVie Inc.?

Does Summit Cancer Centers offer services for Skyrizi patients?

What conditions does Summit Cancer Centers support?